10:54 AM EST, 12/10/2024 (MT Newswires) -- Novartis ( NVS ) said Tuesday that longer-term data from a pivotal phase 3 NATALEE trial of Kisqali as early breast cancer therapy reinforced its efficacy that extends beyond the treatment duration in combination with endocrine therapy.

Latest data showed a sustained reduction in distant recurrence of 28.5% in patients versus endocrine therapy alone, the company said. Reduced distant recurrence - known as distant disease-free survival, or DDFS - refers to decreased rate of cancer returning and spreading to other organs, it said.

The DDFS with Kisqali was observed uniformly among all pre-specified patient subgroups, including those with node-negative disease, the company said.

Novartis ( NVS ) said the late-breaking data presented at the 2024 San Antonio Breast Cancer Symposium also showed that Kisqali's safety profile remains unchanged, with no new safety signals having been identified.

Price: 100.79, Change: -0.89, Percent Change: -0.88